FMO5 and obesity due to melanocortin 4 receptor deficiency: Given the need to find an effective and safe anti-obesogenic agent for a world population where obesity incidence is increasing rapidly (Lin & Li, 2021) we wished to understand if genetic variation in human FMO5 would lead to any of the clinical and metabolic phenotype changes seen in the Fmo5−/− mice.